|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 104.7 USD | +1.91% |
|
+1.58% | -4.90% |
| 07-15 | Equity Markets Higher After Fed Chair Powell's Comments | MT |
| 07-15 | Equity Markets Rise Intraday After Fed Chair Powell's Comments | MT |
(Reuters) - Abbott Laboratories' quarterly profit beat analysts' expectations on Wednesday, aided by strong demand for its diagnostics business and glucose monitoring device FreeStyle Libre.
Excluding one-off items, the healthcare giant reported a profit of $1.03 per share for the fourth quarter ended Dec. 31, higher than the average of analysts' estimate of 92 cents.
The company also announced an adjusted profit forecast of $4.30 to $4.50 per share for 2023.
(Reporting by Leroy Leo and Pratik Jain in Bengaluru; Editing by Sherry Jacob-Phillips)
| 1st Jan change | Capi. | |
|---|---|---|
| -4.90% | 179B | |
| -1.36% | 100B | |
| -7.64% | 46.16B | |
| +18.16% | 44.81B | |
| +9.63% | 44.38B | |
| +13.63% | 29.53B | |
| +22.31% | 25.83B | |
| -7.12% | 23.97B | |
| +4.03% | 22.5B | |
| -8.75% | 22.11B |
ABBOTT LABORATORIES 
